
US-based Regen BioPharma develops and commercializes stem cell therapies for diabetes, heart, and lung diseases.
Regen BioPharma, Inc. focuses on developing and commercializing stem cell therapies aimed at treating diabetes, heart-related illnesses, circulatory issues, and Chronic Obstructive Pulmonary Disease (COPD). The company's core mission is to advance translational medicine platforms to obtain regulatory approval and execute clinical trials in cell therapy. Based in La Mesa, United States, Regen BioPharma aims to bring innovative medical solutions to market, addressing significant unmet medical needs.
Regen BioPharma has made notable strides in the biotechnology sector, particularly in stem cell research and therapy development. The company actively engages with individual and institutional investors, advisors, and analysts through platforms like the Emerging Growth Conference, where it outlines its goals and strategic direction. The leadership includes a proactive Chairman and Chief Executive Officer who regularly communicates with shareholders, underscoring the company's commitment to transparency and growth.

Regenerative Medical Solutions

Regenxbio
regenxbio.com

RegeneRx Biopharmaceuticals

Regenemed
regenemed.com

U.S. Stem Cell
us-stemcell.com

ViaCyte

BioRegenx
bioregenx.com

InGeneron
ingeneron.com

Cellebration Life Sciences

Stemgenics
stemgenics.com

Regenacy Pharmaceuticals

Regennova
regennova.com

Juventas Therapeutics
juventasinc.com

Endogena Therapeutics

Regenerative Bio
regen-bio.us
Companies similar to Regen BioPharma include Regenerative Medical Solutions, Regenxbio, RegeneRx Biopharmaceuticals and Regenemed.
Regen BioPharma was founded in 2012.
Regen BioPharma's headquarters is located in La Mesa, CA, US.
Regen BioPharma has 2 employees as of Feb 5, 2024.